Chimerix, Inc. (CMRX) To Present A Summary Of Brincidofovir's (CMX001) Hematologic Safety At The Annual Meeting Of The European Group For Blood And Marrow Transplantation
3/25/2014 9:15:18 AM
DURHAM, N.C., March 24, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced an upcoming presentation on its investigational broad-spectrum antiviral brincidofovir (CMX001) at the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) being held March 30 – April 2, 2014 in Milan, Italy.
Help employers find you! Check out all the jobs and post your resume.
comments powered by